Drugs / Inactivated Trivalent Influenza Vaccine

Trials 6

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03784885 Sep 2017 → Jan 2018 influenza Advagene Biopharma Co. Ltd. Completed No outcome recorded
Phase 44 trials · 1 met primary · 1 missed
Phase 4 NCT02762851 Jun 2016 → Dec 2019 heart failure, influenza McMaster University Unknown Missed primary
Phase 4 NCT01945268 Apr → Dec 2015 heart failure McMaster University Completed No outcome recorded
Phase 4 NCT01680679 May 2012 → May 2014 influenza University of Colorado, Denver Completed No outcome recorded
Phase 4 NCT00934245 Sep 2009 → Jul 2012 influenza Wayne Sullender, M.D. Completed Met primary
Phase not applicable1 trial
— NCT01713855 Oct 2004 → Mar 2006 autoimmune thrombocytopenic purpura Neufeld, Ellis J, MD, PhD Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT00479648 Comparator May → Aug 2007 influenza Seqirus Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as inactivated trivalent influenza vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01945268 ↗
6

NCT03784885 ↗

NCT00479648 ↗

NCT00934245 ↗

NCT02762851 ↗

NCT01713855 ↗

NCT01680679 ↗

Known as IIV3 “trivalent inactivated influenza vaccine (IIV3)” PMID 31200893 ↗ Jul 2019
Known as TIV “Inactivated split virion trivalent influenza vaccine (TIV)” NCT00934245 ↗
1

“Inactivated Trivalent Influenza Vaccine (TIV)” NCT01680679 ↗

Known as trivalent inactivated influenza vaccine “trivalent inactivated influenza vaccine (IIV3)” PMID 31200893 ↗ Jul 2019
Modality Vaccine “Inactivated trivalent influenza vaccine” NCT00479648 ↗
Route Intramuscular “intramuscular trivalent inactivated influenza vaccine (IIV3)” PMID 31200893 ↗ Jul 2019